Compare INGN & CBUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INGN | CBUS |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.1M | 116.2M |
| IPO Year | 2013 | 2017 |
| Metric | INGN | CBUS |
|---|---|---|
| Price | $5.77 | $1.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $12.00 | ★ $14.33 |
| AVG Volume (30 Days) | ★ 377.8K | 107.2K |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 43.42 | ★ 74.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $348,668,000.00 | $3,639,000.00 |
| Revenue This Year | $2.22 | $42.75 |
| Revenue Next Year | $4.55 | $139.28 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.86 | N/A |
| 52 Week Low | $5.05 | $1.09 |
| 52 Week High | $9.13 | $4.19 |
| Indicator | INGN | CBUS |
|---|---|---|
| Relative Strength Index (RSI) | 59.20 | 49.08 |
| Support Level | $5.48 | $1.48 |
| Resistance Level | $6.73 | $1.62 |
| Average True Range (ATR) | 0.21 | 0.12 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 66.67 | 57.14 |
Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.